Autism Spectrum Disorder Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight's "Autism Spectrum Disorder Pipeline Insight 2025" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Autism Spectrum Disorder pipeline landscape. It covers the Autism Spectrum Disorder Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Autism Spectrum Disorder Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Autism Spectrum Disorder Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/autism-spectrum-disorder-asd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Autism Spectrum Disorder Pipeline Report
• On 21 November 2025, Vertero Therapeutics conducted a study is to establish the potential benefits, safety, and tolerability of AB-2004 in participants with irritability associated with autism spectrum disorder.
• On 19 November 2025, Bazelet Nehushtan Ltd announced a clinical trial is to determine whether (28%) combined with terpenes and a small amount of (1%) can help reduce symptoms of autism, and to evaluate the safety of this treatment.
• DelveInsight's Autism Spectrum Disorder Pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Autism Spectrum Disorder treatment.
• The leading Autism Spectrum Disorder Companies such as Astrogen, MapLight Therapeutics, Axial Therapeutics, Aardvark Therapeutics, Ajna BioSciences, Intra-Cellular Therapies, Finch Therapeutics Group, PharmAla Biotech and others.
• Promising Autism Spectrum Disorder Therapies such as ML-004 (IR)/(ER) tablet, Arbaclofen, Terpenes-Enriched Predominant Oil, Terpenes-Enriched Oil (Free), L1-79, Cannabidivarin, Cariprazine and others.

Want to know which companies are leading innovation in Autism Spectrum Disorder? Dive into the full pipeline insights @ https://www.delveinsight.com/sample-request/autism-spectrum-disorder-asd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Autism Spectrum Disorder Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Autism Spectrum Disorder Pipeline Report also highlights the unmet needs with respect to the Autism Spectrum Disorder.

Autism Spectrum Disorder Overview
Autism spectrum disorder (ASD) is a developmental disability caused by differences in the brain. Some people with ASD have a known difference, such as a genetic condition. Other causes are not yet known. Scientists believe there are multiple Autism Spectrum Disorde causes that act together to change the most common ways people develop. People with ASD may behave, communicate, interact, and learn in ways that are different from most other people. There is often nothing about how they look that sets them apart from other people. The abilities of people with ASD can vary significantly. Autism Spectrum Disorder (ASD) is considered the broad term for autism, but three separate sub-types fit within the ASD category. The 3 types of autism are: Autistic Disorder, Asperger's Syndrome and Pervasive Development Disorder.

Autism Spectrum Disorder Emerging Drugs Profile
• AST-001: Astrogen
AST-001 is a small-molecule drug developed by Astrogen to treat Autism Spectrum Disorder. AST-001 functions as an L-isomer of serine, which plays a critical role in various neurological processes. It has been shown to improve social deficits and restore dopamine neuron activity in preclinical models of ASD. The drug enhances dopamine neuron firing through the normalization of specific ion channel activities, suggesting its potential as a therapeutic agent for improving social interaction and cognitive function in patients with ASD. It targets neurological mechanisms to improve core symptoms in ASD patients and has advanced to Phase III clinical trials following regulatory approval in South Korea.

• ML004: MapLight Therapeutics
ML-004 is MapLight's lead clinical compound. Its selective pharmacological properties of make it a highly specific therapy with limited side effects. The company is developing ML-004 for multiple indications, including sociability and irritability in ASD and agitation and aggression in Alzheimer's disease. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Autism Spectrum Disorder.

• AJA001: Ajna BioSciences
AJA001 is a full-spectrum formulation derived from Cannabis sativa, designed specifically for Autism Spectrum Disorder (ASD). Created through DEFLORIA LLC, a joint venture between Ajna, Charlotte's Web, and BAT, it aims to be the first FDA-approved botanical hemp extract for ASD. Leveraging Charlotte's Web's patented genetics, AJA001 optimizes bioavailability, showing promising symptom relief and quality-of-life improvements in early clinical trials.

If you're tracking ongoing Autism Spectrum Disorder Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ https://www.delveinsight.com/sample-request/autism-spectrum-disorder-asd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Autism Spectrum Disorder Pipeline report provides insights into:-
• The report provides detailed insights about companies that are developing therapies for the treatment of Autism Spectrum Disorder with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Autism Spectrum Disorder Treatment.
• Autism Spectrum Disorder Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Autism Spectrum Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Autism Spectrum Disorder market.

Autism Spectrum Disorder Companies
Astrogen, MapLight Therapeutics, Axial Therapeutics, Aardvark Therapeutics, Ajna BioSciences, Intra-Cellular Therapies, Finch Therapeutics Group, PharmAla Biotech and others.

Autism Spectrum Disorder Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Autism Spectrum Disorder Products have been categorized under various Molecule types such as,
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Autism Spectrum Disorder Pipeline Report covers it all - check it out now @ https://www.delveinsight.com/sample-request/autism-spectrum-disorder-asd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Autism Spectrum Disorder Pipeline Report
• Coverage- Global
• Autism Spectrum Disorder Companies- Astrogen, MapLight Therapeutics, Axial Therapeutics, Aardvark Therapeutics, Ajna BioSciences, Intra-Cellular Therapies, Finch Therapeutics Group, PharmAla Biotech and others.
• Autism Spectrum Disorder Therapies- ML-004 (IR)/(ER) tablet, Arbaclofen, Terpenes-Enriched Predominant Oil, Terpenes-Enriched Oil (Free), L1-79, Cannabidivarin, Cariprazine and others.
• Autism Spectrum Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Autism Spectrum Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Research - discover what's next for the Autism Spectrum Disorder Treatment landscape in this detailed analysis @ https://www.delveinsight.com/sample-request/autism-spectrum-disorder-asd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Autism Spectrum Disorder: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Autism Spectrum Disorder- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. AST-001: Astrogen
9. Mid Stage Products (Phase II)
10. ML004: MapLight Therapeutics
11. Early Stage Products (Phase I)
12. AJA001: Ajna BioSciences
13. Preclinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Autism Spectrum Disorder Key Companies
17. Autism Spectrum Disorder Key Products
18. Autism Spectrum Disorder- Unmet Needs
19. Autism Spectrum Disorder- Market Drivers and Barriers
20. Autism Spectrum Disorder- Future Perspectives and Conclusion
21. Autism Spectrum Disorder Analyst Views
22. Autism Spectrum Disorder Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.